株式会社 SEMABIZ - 市場データ・産業調査レポート販売
BCC Research

GLP-1アナログの世界市場

Global GLP-1 Analogues Market


出版 BCC Research
出版年月 2025年12月
ページ数 85
価格 記載以外のライセンスについてはお問合せください
 シングルユーザ USD 2,950.00
 企業ライセンス USD 5,100.00
種別 英文調査報告書
商品番号 SMR-11448


SEMABIZ - otoiawase8

Report Highlights

This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Report Includes

  • An overview of the current and future global markets for GLP-1 analogues
  • In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
  • Estimates of the size and revenue prospects of the global market, along with a market share analysis by route of administration, indication and region
  • Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors
  • An analysis of patents, emerging trends and developments in the industry
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
  • Profiles of the leading companies

Report Scope

This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.

The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.

The report aims to:

  • Analyze the market for GLP-1 analogues.
  • Analyze the global market size and market segments.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts for 2030.
  • Assess market share, competitiveness and industry structure.
  • Identify potential long-term impacts on the GLP-1 analogue market.

Report Synopsis

Report Metrics Details
Base year considered 2024
Forecast period considered 2025-2030
Base year market size $54.8 billion
Market size forecast $268.4 billion
Growth rate CAGR of 30.6% for the forecast period of 2025-2030
Units considered $ Millions
Segments covered Route of Administration, Region
Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa
Countries covered U.S., Canada, Mexico, U.K., Italy, France, Germany, Spain, Austria, Denmark, the Netherlands, Poland, Sweden, Switzerland, China, India, Japan, Malaysia, Australia, South Korea, Singapore, Thailand, Brazil, Argentina, Colombia, Paraguay, Peru
Key Market Drivers
  • Increasing Cases of Diabetes and Obesity
  • Increasing Awareness of Diagnosis and Treatment Options for Diabetes
  • Strong R&D Pipeline
Companies studied
TEVA PHARMACEUTICAL INDUSTRIES LTD. SHANGHAI BENEMAE PHARMACEUTICAL CORP.
SANOFI NOVO NORDISK A/S
LILLY USA LLC. HANSOH PHARMACEUTICAL GROUP CO. LTD.

Table of Contents

Chapter- 1: Executive Summary
Chapter- 2: Market Overview
Chapter- 3: Market Dynamics
Chapter- 4: Regulatory Landscape
Chapter- 5: Emerging Technologies and Pipeline Analysis
Chapter- 6: Market Segment Analysis
Chapter- 7: Competitive Intelligence
Chapter- 8: Sustainability in GLP-1 Analogues: ESG Perspective
Chapter- 9: Appendix


    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    お問合せレポート

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    SEMABIZのプライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    inquiry(at)semabiz.co.jp


    関連記事